ATE427351T1 - Primaten t-lymphotrophische viren - Google Patents
Primaten t-lymphotrophische virenInfo
- Publication number
- ATE427351T1 ATE427351T1 AT06735500T AT06735500T ATE427351T1 AT E427351 T1 ATE427351 T1 AT E427351T1 AT 06735500 T AT06735500 T AT 06735500T AT 06735500 T AT06735500 T AT 06735500T AT E427351 T1 ATE427351 T1 AT E427351T1
- Authority
- AT
- Austria
- Prior art keywords
- htlv
- primate
- htlvs
- novel
- variety
- Prior art date
Links
- 241000288906 Primates Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title abstract 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 abstract 3
- 241000713310 Human T-cell lymphotropic virus type 4 Species 0.000 abstract 3
- 241001136003 Human T-lymphotropic virus 3 Species 0.000 abstract 3
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241000713309 Simian immunodeficiency virus - agm Species 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14041—Use of virus, viral particle or viral elements as a vector
- C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65448405P | 2005-02-21 | 2005-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE427351T1 true ATE427351T1 (de) | 2009-04-15 |
Family
ID=36655074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09075152T ATE539153T1 (de) | 2005-02-21 | 2006-02-21 | Primaten t-lymphotrophische viren |
| AT06735500T ATE427351T1 (de) | 2005-02-21 | 2006-02-21 | Primaten t-lymphotrophische viren |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09075152T ATE539153T1 (de) | 2005-02-21 | 2006-02-21 | Primaten t-lymphotrophische viren |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7794998B2 (de) |
| EP (2) | EP1880006B1 (de) |
| AT (2) | ATE539153T1 (de) |
| AU (1) | AU2006216838B8 (de) |
| CA (1) | CA2598547C (de) |
| DE (1) | DE602006006047D1 (de) |
| WO (1) | WO2006091511A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE539153T1 (de) | 2005-02-21 | 2012-01-15 | Us Gov Health & Human Serv | Primaten t-lymphotrophische viren |
| WO2006133795A2 (en) * | 2005-05-02 | 2006-12-21 | Institut Pasteur | A new human t-cell lymphotropic virus (htlv-3): nucleic acid and peptidic sequences thereof and method for detecting htlv-3 |
| CA2688724C (en) | 2007-05-21 | 2016-03-29 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Novel simian t-cell lymphotropic virus |
| US10928398B2 (en) * | 2008-12-17 | 2021-02-23 | Cornell University | Method for double staining colocalized nuclear-markers in histological lymphoid or bone marrow tissue sample |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| WO2014081882A2 (en) * | 2012-11-20 | 2014-05-30 | The Trustees Of Columbia University In The City Of New York | Systems and methods for analyzing coding sequences based on genetic distances |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406841B1 (en) | 1993-07-01 | 2002-06-18 | Abbott Laboratories | Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides |
| ATE539153T1 (de) * | 2005-02-21 | 2012-01-15 | Us Gov Health & Human Serv | Primaten t-lymphotrophische viren |
-
2006
- 2006-02-21 AT AT09075152T patent/ATE539153T1/de active
- 2006-02-21 EP EP06735500A patent/EP1880006B1/de not_active Expired - Lifetime
- 2006-02-21 DE DE602006006047T patent/DE602006006047D1/de not_active Expired - Lifetime
- 2006-02-21 AU AU2006216838A patent/AU2006216838B8/en not_active Ceased
- 2006-02-21 EP EP09075152A patent/EP2194127B1/de not_active Expired - Lifetime
- 2006-02-21 AT AT06735500T patent/ATE427351T1/de not_active IP Right Cessation
- 2006-02-21 WO PCT/US2006/005869 patent/WO2006091511A2/en not_active Ceased
- 2006-02-21 CA CA2598547A patent/CA2598547C/en not_active Expired - Fee Related
-
2007
- 2007-02-24 US US11/678,596 patent/US7794998B2/en not_active Expired - Fee Related
-
2010
- 2010-07-01 US US12/829,125 patent/US8541221B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,914 patent/US9435000B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006006047D1 (en) | 2009-05-14 |
| US8541221B2 (en) | 2013-09-24 |
| EP1880006B1 (de) | 2009-04-01 |
| EP2194127A1 (de) | 2010-06-09 |
| US20140080121A1 (en) | 2014-03-20 |
| EP2194127B1 (de) | 2011-12-28 |
| WO2006091511A3 (en) | 2006-12-28 |
| US7794998B2 (en) | 2010-09-14 |
| CA2598547A1 (en) | 2006-08-31 |
| WO2006091511A2 (en) | 2006-08-31 |
| US20080292657A1 (en) | 2008-11-27 |
| CA2598547C (en) | 2016-01-19 |
| EP1880006A2 (de) | 2008-01-23 |
| US9435000B2 (en) | 2016-09-06 |
| US20100317034A1 (en) | 2010-12-16 |
| AU2006216838B8 (en) | 2011-05-12 |
| ATE539153T1 (de) | 2012-01-15 |
| AU2006216838A1 (en) | 2006-08-31 |
| WO2006091511A8 (en) | 2007-11-22 |
| AU2006216838B2 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peterhans et al. | Pestiviruses: how to outmaneuver your hosts | |
| MA33642B1 (fr) | Composés chimiques | |
| ECSP044933A (es) | Método y montaje para aumentar el volumen del cabello | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
| UA94717C2 (ru) | Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| DK1942108T3 (da) | Forbindelse indeholdende basisk gruppe samt anvendelse deraf | |
| EA200701113A1 (ru) | Макролиды | |
| ATE427351T1 (de) | Primaten t-lymphotrophische viren | |
| EA201500643A1 (ru) | Парвовирус свиней 5а, способы применения и вакцина | |
| MX2012003827A (es) | Toxina rtx citolitica de gallibacterium anatis. | |
| WO2009005040A1 (ja) | 緑膿菌の外膜タンパク質pa4710 | |
| BR0314640A (pt) | Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida | |
| MX2022003218A (es) | Vacunas para abejas y metodos de uso. | |
| WO2005084315A3 (en) | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease | |
| Aslan et al. | The evaluation of oxidative stress in lambs with Pestivirus infection | |
| WO2007065007A3 (en) | Treatment of viral infections | |
| WO2007036735A3 (en) | Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei | |
| Mustafa et al. | Pandemic SARS Coronavirus-2 infections in humans-COVID-19 | |
| EA201591095A1 (ru) | Белок slurp-1 для применения в лечении глазных болезней | |
| Kushawaha et al. | Nipah virus and its outbreaks in tropical areas | |
| Kalugina et al. | Studying of efficiency" Duo Ekvalan" at helminthoses of horses | |
| NO20075272L (no) | Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser | |
| Amaechi et al. | Comparative efficacy of diaminazine aceturate and isomethamidium chloride in rabbits experimentally infected with Trypanosoma brucei brucei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |